Novartis Ag (NVS) Cash from Financing Activities (2009 - 2025)
Novartis Ag recorded quarterly Cash from Financing Activities of -$5.2 billion in Q2 2025, up 37.67% quarter-over-quarter from -$8.4 billion in Q4 2024, and down 62.91% year-over-year from -$14.1 billion in Q2 2024.
Novartis Ag's Cash from Financing Activities history runs 15 years deep, the most recent figure standing at -$5.2 billion for Q2 2025.
- In Q2 2025, Cash from Financing Activities fell 62.91% year-over-year to -$5.2 billion; the TTM figure through Jun 2025 stood at -$17.2 billion (down 209.84% YoY), while the FY2025 annual figure was -$14.9 billion, down 26.61% from the prior year.
- Cash from Financing Activities came in at -$5.2 billion for Q2 2025 at Novartis Ag, up from -$8.4 billion in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $11.1 billion in Q3 2021 to a low of -$11.8 billion in Q4 2022.
- A 5-year average of -$2.8 billion and a median of -$2.6 billion in 2021 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities soared 485.47% in 2021 and tumbled 1277.92% in 2024, its largest moves.
- Novartis Ag's Cash from Financing Activities stood at -$11.5 billion in 2021, then dropped by 3.06% to -$11.8 billion in 2022, then jumped by 94.87% to -$607.0 million in 2023, then sank by 1277.92% to -$8.4 billion in 2024, then jumped by 37.67% to -$5.2 billion in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$5.2 billion, -$8.4 billion, and -$382.0 million for Q2 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -3.47 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 530.00 Mn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 919.00 Mn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -2.98 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 1.44 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | -4.24 Bn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | -2.86 Bn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -1.56 Bn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -5.21 Bn |
| Jun 30, 2025 | -5.21 Bn |
| Dec 31, 2024 | -8.36 Bn |
| Dec 31, 2024 | -8.36 Bn |
| Sep 30, 2024 | -382.00 Mn |
| Sep 30, 2024 | -382.00 Mn |
| Jun 30, 2024 | -3.20 Bn |
| Jun 30, 2024 | -3.20 Bn |
| Mar 31, 2024 | -899.00 Mn |
| Mar 31, 2024 | -899.00 Mn |
| Dec 31, 2023 | -607.00 Mn |
| Dec 31, 2023 | -607.00 Mn |
| Sep 30, 2023 | -832.00 Mn |
| Sep 30, 2023 | -832.00 Mn |
| Jun 30, 2023 | -3.64 Bn |
| Jun 30, 2023 | -3.64 Bn |
| Dec 31, 2022 | -11.83 Bn |
| Dec 31, 2022 | -11.83 Bn |
| Jun 30, 2022 | -2.30 Bn |
| Jun 30, 2022 | -2.30 Bn |
| Dec 31, 2021 | -11.48 Bn |
| Dec 31, 2021 | -11.48 Bn |
| Sep 30, 2021 | 11.12 Bn |
| Sep 30, 2021 | 11.12 Bn |
| Jun 30, 2021 | -2.94 Bn |
| Jun 30, 2021 | -2.94 Bn |
| Mar 31, 2021 | 785.00 Mn |
| Mar 31, 2021 | 785.00 Mn |
| Dec 31, 2020 | -1.17 Bn |
| Dec 31, 2020 | -1.17 Bn |
| Sep 30, 2020 | 1.90 Bn |
| Sep 30, 2020 | 1.90 Bn |
| Jun 30, 2020 | -2.19 Bn |
| Jun 30, 2020 | -2.19 Bn |
| Jun 30, 2019 | -28.00 Mn |
| Jun 30, 2019 | -28.00 Mn |
| Dec 31, 2018 | 453.00 Mn |
| Dec 31, 2018 | 453.00 Mn |
| Jun 30, 2018 | -1.53 Bn |
| Jun 30, 2018 | -1.53 Bn |
| Jun 30, 2017 | -3.01 Bn |
| Jun 30, 2017 | -3.01 Bn |
| Mar 31, 2017 | -388.00 Mn |
| Mar 31, 2017 | -388.00 Mn |
| Sep 30, 2016 | -342.00 Mn |
| Sep 30, 2016 | -342.00 Mn |
| Dec 31, 2014 | -742.00 |
| Dec 31, 2014 | -742.00 |
| Dec 31, 2013 | 97.00 |
| Dec 31, 2013 | 97.00 |
| Mar 31, 2011 | -487.00 |
| Mar 31, 2011 | -487.00 |
| Dec 31, 2010 | 972.00 |
| Dec 31, 2010 | 972.00 |
| Jun 30, 2010 | 950.00 |
| Jun 30, 2010 | 950.00 |
| Mar 31, 2010 | 22.00 |
| Mar 31, 2010 | 22.00 |
| Dec 31, 2009 | -141.00 |
| Dec 31, 2009 | -141.00 |
| Sep 30, 2009 | 443.00 |
| Sep 30, 2009 | 443.00 |
| Jun 30, 2009 | -2,732.00 |
| Jun 30, 2009 | -2,732.00 |
| Mar 31, 2009 | 452.00 |
| Mar 31, 2009 | 452.00 |